SREBF2 and hepatocellular carcinoma: As the first study to integrate SREBP2 into LT candidate selection, this biologically informed nomogram significantly enhances recurrence prediction, offering a refined tool for transplant eligibility assessment and adjuvant therapy guidance in HCC management.